Home › UPDATE 2-Celgene to stop blood cancer trial due to high death rates
 

Keywords :   


UPDATE 2-Celgene to stop blood cancer trial due to high death rates

2013-07-18 23:40:32| Biotech - Topix.net

Celgene Corp said it will stop a late-stage trial of its blood cancer drug, Revlimid, after it observed a higher number of deaths in elderly leukemia patients taking the drug compared with those on another treatment.

Tags: high due rates update

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
26.06Atlantic Tropical Weather Outlook
26.06Eastern North Pacific Tropical Weather Outlook
26.06XREAL bring Play Store apps to 3D space on XREAL AR glasses
26.06Qwilt reveals live streaming survey results
26.06Rockline Industries Wins WOW Innovation Award
26.06IMS Technologies Expands Calcinate Production Site
26.06Horizon expert 'gave evidence based on informal chats'
26.06Automotive Color by BASF Recognized with Renowned Red Dot Award
More »